Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: A dose-finding trial

Neurology

Volumn 71, Issue 4, 2008, Pages 265-271

  Fazekas, F ^a   Lublin, F D ^b   Li, D ^c   Freedman, M S ^d   Hartung, H P ^e   Rieckmann, P ^f   Sørensen, P Soelberg ^g   Maas Enriquez, M ^h   Sommerauer, B ⁱ   Hanna, K ^j  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g University of Copenhagen   (Denmark)

^h BAYER PHARMA AG   (Germany)

ⁱ BAYER AG   (Germany)

^j Talecris Biotherapeutics Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DISEASE ACTIVITY; DISEASE FREE INTERVAL; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HERPES ZOSTER OPHTHALMICUS; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VASCULITIS; ADOLESCENT; CENTRAL NERVOUS SYSTEM; DISABILITY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CENTRAL NERVOUS SYSTEM; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PLACEBOS; RECURRENCE; TREATMENT OUTCOME;

EID: 50549098795     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000318281.98220.6f     Document Type: Article

References (21)

1. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B; for Austrian Immunoglobulin in Multiple Sclerosis Study Group. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997;349: 589-593.
2. Achiron A, Gabbay U, Gilad R, et al. Intravenous immu-noglobulin treatment in multiple sclerosis: effect on relapses. Neurology 1998;50:398-402.
3. Sørensen P, Wanscher B, Jensen C, et al. Intravenous im-munoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998;50:1273-1281.
4. Lewanska M, Siger-Zajdel M, Selmaj K. No difference in efficacy of two different doses of intravenous immuno-globulins in MS: clinical and MRI assessment. Eur J Neu-rol 2002;9:565-572.
5. McDonald W, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guide- lines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127.
6. Lublin F, Reingold S. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911.
7. Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
8. Cutter G, Baier M, Rudick R, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871-882.
9. Li D, Zhao G, Paty D; University of British Columbia MS/MRI Analysis Research Group, SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001;56:1505-1513.
10. Li D, Li M, Traboulsee A, Zhao G, Riddehough A, Paty D. The use of MRI as an outcome measure in clinical trials. Adv Neurol 2006;98:203-226.
11. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006;67:944-953.
12. Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis: new aspects and practical application. J Neurol 2004;251:1329-1339.
13. Sørensen P, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 2002;2002:557-563.
14. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
15. Jacobs L, Cookfair D, Rudick R, et al. Intramuscular inter-feron beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
16. PRISMS (Prevention of Relapses and Disability by Inter-feron beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
17. Achiron A, Kishner I, Sarova-Pinhas I, et al. Intravenous immunoglobulin treatment following the first demyelinat-ing event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 2004; 61:1515-1520.
18. Polman C, O'Connor P, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
19. Kappos L, Moeri D, Radue E, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a metaanalysis. Lancet 1999;353:964-969.
20. Hommes O, Soerensen P, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised, placebo-controlled trial. Lancet 2004; 364:1149-1156.
21. Fazekas F, Sorensen P, Filippi M, et al. MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Mult Scler 2005;11:433-440.